Use of mHealth interventions in the management of chemotherapy-related adverse drug reactions
BackgroundChemotherapy remains a cornerstone of cancer treatment but carries a substantial burden of adverse drug reactions (ADRs), poorly managed after patients leave hospital. mHealth technologies offer a scalable way to remotely monitor, report, prevent, and manage ADRs. No review has mapped mHealth functionality for chemotherapy-related ADR management across cancer types.ObjectivesTo map existing evidence on mHealth interventions used for monitoring, reporting, preventing, or managing chemotherapy-related ADRs among cancer patients, and to identify gaps for future research.MethodsThis review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and Population-Concept-Context approach. A systematic search of PubMed and Scopus identified studies evaluating mHealth interventions (apps, SMS systems, telemonitoring platforms, or wearables) for chemotherapy-related ADRs in cancer patients of any age or setting. Data were charted on study characteristics, intervention functionality, and outcomes, then synthesized narratively.Results7 studies (one RCT, one non-randomized trial, two systematic reviews, one with meta-analysis, two observational studies, one non-randomized study) met inclusion criteria, mostly in breast cancer (71%) and delivered via smartphone apps (86%). Monitoring was universal (100%); reporting and management were each present in 71% of studies; prevention was weakest (29%, always secondary). Benefit tracked with pairing monitoring to active management: severe ADR incidence fell from 50.0% to 20.2%, quality of life improved significantly (SMD = 0.31, p < 0.0001), and alerts showed 72% positive predictive value. Monitoring-only platforms improved usability without clinical gains.ConclusionmHealth interventions show promise for chemotherapy ADR management, but benefits depend on linking monitoring to reporting and management rather than monitoring alone; prevention remains a key gap.
Authors
- Tejaswini Bangalore Darukaradhya (ORCID: https://orcid.org/0000-0001-6567-9067)
- G Hari Prakash (ORCID: https://orcid.org/0000-0002-9463-4084)
- Anush Nayak (ORCID: https://orcid.org/0000-0002-8121-2958)
- O Amulya (ORCID: https://orcid.org/0009-0002-7813-5186)
- Renushree BS (ORCID: https://orcid.org/0009-0007-9003-1634)
Institutions
- M S Ramaiah University of Applied Sciences (IN)
Publication Details
- Journal
- Journal of Oncology Pharmacy Practice
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1177/10781552261509556
- Primary Topic
- Mobile Health and mHealth Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00